BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils

por Smiljkovic, D., Blatt, K., Stefanzl, G., Dorofeeva, Y., Skrabs, C., Focke‐Tejkl, M., Sperr, W. R., Jaeger, U., Valenta, R., Valent, P.
Publicado 2017

P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVA...

por Jaeger, U., Broome, C., Go, R., Patriarca, A., Roeth, A., Chang, Q., Weedin, N., Adams, P., Cahir-McFarland, E., Kroon, H.-A.
Publicado 2022

P1107: CLINICAL OUTCOMES OF SOLID ORGAN TRANSPLANT PATIENTS WITH EBV+ PTLD WHO FAIL RITUXIMAB PLUS CHEMOTHERAPY: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY

por Dharnidharka, V., Thirumalai, D., Jaeger, U., Zhao, W., Dierickx, D., Xun, P., Minga, P., Sawas, A., Sadetsky, N., Chauvet, P., Sundaram, E., Barlev, A., Zimmerman, H., Trappe, R. U.
Publicado 2022

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib

por Kazianka, L, Drucker, C, Skrabs, C, Thomas, W, Melchardt, T, Struve, S, Bergmann, M, Staber, P B, Porpaczy, E, Einberger, C, Heinz, M, Hauswirth, A, Raderer, M, Pabinger, I, Thalhammer, R, Egle, A, Wendtner, C-M, Follows, G, Hoermann, G, Quehenberger, P, Jilma, B, Jaeger, U
Publicado 2017

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

por Brown, J R, Hillmen, P, O’Brien, S, Barrientos, J C, Reddy, N M, Coutre, S E, Tam, C S, Mulligan, S P, Jaeger, U, Barr, P M, Furman, R R, Kipps, T J, Cymbalista, F, Thornton, P, Caligaris-Cappio, F, Delgado, J, Montillo, M, DeVos, S, Moreno, C, Pagel, J M, Munir, T, Burger, J A, Chung, D, Lin, J, Gau, L, Chang, B, Cole, G, Hsu, E, James, D F, Byrd, J C
Publicado 2018